ZD Medical is a technology company.
ZD Medical has raised $21.0M across 2 funding rounds.
ZD Medical has raised $21.0M in total across 2 funding rounds.
ZD Medical has raised $21.0M in total across 2 funding rounds.
ZD Medical's investors include Qiming Venture Partners.
ZD Medical is a technology company specializing in the development and manufacturing of advanced ophthalmic medical devices, particularly optical coherence tomography (OCT) scanners and equipment for diagnosing and treating xerophthalmia (dry eye disease). Their products serve ophthalmologists and eye care professionals by providing high-precision, cost-effective diagnostic and therapeutic platforms that improve the quality of eye care and patient outcomes. The company has demonstrated strong growth momentum through innovation, international certifications, and strategic partnerships, positioning itself as a leading provider of ophthalmic imaging and diagnostic solutions in China and expanding globally with R&D centers in the USA[1][2][3].
Founded in 2015, ZD Medical emerged from a strong foundation in optical system research and medical device innovation. The company was established with a focus on leveraging cutting-edge optical coherence tomography technology to address unmet needs in ophthalmology, particularly in diagnosing retinal diseases and dry eye conditions. The founding team includes experts in optics and medical imaging, supported by a robust R&D infrastructure in Hangzhou, China, and research centers in Los Angeles and Silicon Valley. Early pivotal moments include the launch of their OCTA/OCT products in 2018, certification as a high-tech enterprise, and strategic collaborations such as the 2022 partnership with the Suzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences to advance ophthalmic clinical applications[1][2].
ZD Medical rides the global trend of integrating advanced imaging technologies and artificial intelligence into medical diagnostics, particularly in ophthalmology. The timing is critical as eye diseases like dry eye and retinal degeneration are increasingly prevalent due to aging populations and lifestyle factors. Market forces such as rising demand for non-invasive, precise diagnostic tools and growing healthcare infrastructure in China and worldwide favor ZD Medical’s growth. By advancing optical coherence tomography technology and fostering international collaborations, ZD Medical influences the broader ecosystem by improving diagnostic capabilities, reducing missed diagnoses, and supporting better patient outcomes in eye care[1][2][3].
ZD Medical is poised to expand its influence through continued investment in R&D, especially in ophthalmic artificial intelligence and international market penetration. Future trends shaping their journey include the integration of AI for image reading, the rise of personalized eye care, and increasing global demand for affordable diagnostic devices. Their strategic partnerships and innovation pipeline suggest sustained growth and leadership in ophthalmic technology. As they deepen their technological capabilities and global footprint, ZD Medical is likely to become a key player in transforming eye disease diagnosis and treatment worldwide, fulfilling their mission to enhance the quality of eye life globally[1][2].
ZD Medical has raised $21.0M across 2 funding rounds. Most recently, it raised $4.0M Series A in May 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2019 | $4.0M Series A | Qiming Venture Partners | |
| Mar 1, 2018 | $17.0M Series A | Qiming Venture Partners |